Trial document

drksid header


Trial Description

start of 1:1-Block title


Incidence and risk factors of viral infections in patients after liver transplantation

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Today in specialized hospitals, liver transplantation are routine operations in case of severe chronic liver diseases. As a result of the following immunosuppression, these patients own a higher risk for viral infections. Known is that in case of a viral infection the risk for graft fail is clearly increased. That’s why liver-transplanted patients receive a prophylaxis with antiviral medicaments. These medicaments have unwished side effects and cannot prevent infections in all patients.
The presented study has the goal to indicate the incidence of viral infections in liver transplanted patients. In the same time the determination of risk factors and prognostic parameter will take place to perhaps decrease the risk of graft failure. The earlier detection and estimation of an invasive viral infection in liver- transplanted patients can help to develop new therapeutic strategies and to better indicate the necessity of an antiviral prophylaxis to increase the patient’s outcome.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

The orthotopic liver transplantation is a routinely used procedure to give patients with acute liver failure or severe chronic liver diseases the chance to survive. The innovations of the last years gave them the possibility to have a longer life in combination with a higher quality of life.
In some cases primary and secondary graft failure can occur and leads to the necessity of a re-transplantation or patient’s death. For viral infection in liver-transplanted patients it is know, that they are associated with a worse outcome.
That’s why normally an antiviral prophylaxis is given, but these medicaments are associated with unwished side effects and cannot prevent infections in every case.
The goal of the presented study is to indicate the incidence of viral infections in liver transplanted patients and to find a differentiation between harmless colonization and invasive infection. Further prognostic parameter should be found to determinate the risk for viral infections in liver transplanted patients to elevate the patient’s outcome.
Clinical laboratory parameter like the kinetic of the liver enzymes, liver synthesis parameter and the relevant clinical scores (MELD, SOFA, APACHE II) will be examined. For the viral diagnostics antigenes, serological parameters (immunoglobulins) and PCR for viral-DNA will be executed. The earlier detection and estimation can help to determine the necessity of a antiviral prophylaxis and to develop new therapy strategies to minimize the risk for a graft failure or patient’s death.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00006754
  •   2014/09/17
  •   [---]*
  •   yes
  •   Approved
  •   S-336/2014, Ethik-Kommission I der Medizinischen Fakultät Heidelberg
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

    Patients undergoing orthotopic liver transplantation from deceased donors
  •   K74.6 -  Other and unspecified cirrhosis of liver
  •   C22.0 -  Malignant neoplasm: Liver cell carcinoma
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   80 patients with liver transplantation will be included. The following parameters will be screened on day 0-1-2-7-14-21-28 after transplantation: Anamnesis (acute/chronic), general infectiology (leucocytes, CRP, PCT, temp.), inflammatory monitoring (sCD14-ST, AChE, IL-6, TNF-alpha), general laboratory testing, hemodynamic (MAP, HR, CVP, CI, SVR, PVR) & need for catecholamines, ventilation ((FiO2, AMV, AF, VT, PEEP), blood gazes, bilancing, metabolism, organ failure, general and immunosupressive medication and determination regularly the MELD, APACHE II, SOFA, Child-Pugh -scores. The indication of a viral infection will be made by PCR of HSV- and CMV-DNA from throat swab and blood serum, detection of the speficic antibodies and the antigens from blood serum and the detection of pp65 from peripheral leucocytes. In intubated/tracheotomated patient’s tracheal secretion will be also used to perform HSV-and CMV-DNA-PCR.
end of 1:N-Block interventions
start of 1:1-Block design


  •   Non-interventional
  •   Other
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Prognosis
  •   Single (group)
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Incidence and progress of viral infections in patients with liver transplantation. The determination of the initial viral findings and the course by using ELISA- and PCR-methods (Polymerase Chain Reaction) for HSV (herpes simplex virus) and CMV (Cytomegalovirus) detection from blood plasma. The effectiveness of an antiviral prophylaxis to prevent invasive viral infection will also be determined.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Estimation of the validity of scoring systems (APACHE II, SOFA, MELD) and clinical laboratory parameters for the prognosis of viral infection in liver transplanted patients. Development of a scoring system to estimate the infection risk and to reduce the over-treatment. Evaluation of acetylcholinesterase and butyrilcholinesterase as new marker for synthesis performance of the new donor organ or as preterm infection parameter.

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   Actual
  •   2014/11/03
  •   80
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

• Liver transplantation at the center of transplantation in Heidelberg
• Written and signed informt consent
• Age > 18 years

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

Non-Compliance to the including criteria’s

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Klinik für Anaesthesiologie Universitätsklinikum Heidelberg
    • Mr.  Prof. Dr. med  Stefan  Hofer 
    • Im Neuenheimer Feld 110
    • 69120  Heidelberg
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
  • start of 1:1-Block address otherSupport
    • Heidelberger Stiftung Chirurgie
    • Im Neuenheimer Feld 110
    • 69120  Heidelberg
    • Germany
    end of 1:1-Block address otherSupport
    start of 1:1-Block address contact otherSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact otherSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting complete, follow-up complete
  •   2016/03/14
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.